NVCR - NovoCure Removes Overhang Secures CMC Coverage For Newly-Diagnosed GBM

Introduction

I first introduced the story of NovoCure (NVCR) in November 2017 when shares were trading below $20.

Today, shares of NovoCure trade near $70.

I was interested in NovoCure's new modality to treat cancer: the use of tumor treating fields that work to upset broken & steadfast division of cancerous cells. Since then, NovoCure has revealed data in mesothelioma (thoracic cancer) that is also suggestive of benefit. Importantly, the benefit of tumor treating fields seems to extend beyond the home of the skull. If this is, indeed, the case, NovoCure's modality could

Read more ...